Human interleukin-2

未知生产厂商

Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

技术标识符

UNII ID: FNO32LO217

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

LONG-ACTING RECOMBINANT HUMAN INTERLEUKIN-2 FUSION PROTEIN, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
EP 4393958 A1申请人: BEIJING VDJBIO CO LTD优先权: 2021
CN
EP
US
WO
10 件公开
COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY
EP 4461742 A3申请人: BIONIZ THERAPEUTICS INC优先权: 2011
EP
US
10 件公开
IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
EP 3402819 C0申请人: UNIV ZUERICH优先权: 2016
CN
EP
US
WO
9 件公开
Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells
US 11618885 B2申请人: CANCER RESEARCH TECH LTD优先权: 2015
CN
EP
US
WO
8 件公开
HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAC DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
EP 4139340 A1申请人: MERCK SHARP & DOHME LLC优先权: 2020
CN
EP
US
WO
6 件公开
HUMAN V GAMMA 9V DELTA 2T CELL PROLIFERATION CULTURE METHOD AND CULTURE MEDIUM
EP 3904506 C0申请人: GUANGDONG GD KONGMING BIOTECH LLC优先权: 2018
CN
EP
US
WO
5 件公开
Anti-human interleukin 23 monoclonal antibody and application thereof
US 12692303 B1申请人: QYUNS THERAPEUTICS CO LTD优先权: 2020
CN
EP
US
WO
5 件公开
MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM THE HUMAN INTERLEUKIN-2 RECEPTOR GAMMA CHAIN GENE AND USES THEREOF
US 2011091441 A1申请人: CELLECTIS优先权: 2007
EP
US
WO
5 件公开
CA2-IL15 FUSION PROTEINS FOR TUNABLE REGULATION
EP 4028413 A1申请人: OBSIDIAN THERAPEUTICS INC优先权: 2019
CN
EP
US
5 件公开
LOW DOSE HUMAN INTERLEUKIN-2 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
EP 4647123 A2申请人: CENTRE HOSPITALIER UNIV DE NIMES优先权: 2020
EP
US
WO
5 件公开

药物